Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer

Breast Cancer Research and Treatment

Volumn 130, Issue 3, 2011, Pages 825-831

  Pippen, John ^a,b,c   Paul, Devchand ^d   Vukelja, Svetislava ^a   Clawson, Alicia ^e   Iglesias, Jose ^e  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b TEXAS ONCOLOGY   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d Rocky Mountain Cancer Center   (United States)

^e CELGENE CORPORATION   (United States)

Author keywords

AC therapy; Albumin bound paclitaxel; Bevacizumab; Dose dense; Early stage breast cancer

Indexed keywords

ALBUMIN BOUND PACLITAXEL; BEVACIZUMAB; CREMOPHOR BASED PACLITAXEL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CONTROLLED STUDY; DOSE DENSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ALBUMIN-BOUND PACLITAXEL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; TREATMENT OUTCOME;

EID: 82255175820     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1678-9     Document Type: Article

References (17)

1. M Campone P Fumoleau E Bourbouloux, et al. 2005 Taxanes in adjuvant breast cancer setting: which standard in Europe? Crit Rev Oncol Hematol 55 167 175 16039867 10.1016/j.critrevonc.2005.04.003 (Pubitemid 41219689)
2. ML Citron DA Berry C Cirrincione, et al. 2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 1431 1439 12668651 10.1200/JCO.2003.09.081 1:CAS:528:DC%2BD2cXptlCks7s%3D (Pubitemid 46594092)
3. Hayes DF, Thor A, Dressler L et al. (2006) HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J Clin Oncol (Meeting Abstracts) 24:Abstr#510
4. IC Henderson V Bhatia 2007 Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy Expert Rev Anticancer Ther 7 919 943 17627452 10.1586/14737140.7.7.919 1:CAS:528: DC%2BD2sXnvVersrg%3D (Pubitemid 47180894)
5. NK Ibrahim N Desai S Legha, et al. 2002 Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin Cancer Res 8 1038 1044 12006516 1:CAS:528:DC%2BD38XksVSqurg%3D (Pubitemid 34517637)
6. WJ Gradishar S Tjulandin N Davidson, et al. 2005 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 7794 7803 16172456 10.1200/JCO.2005.04.937 1:CAS:528:DC%2BD2MXht1Cqs7nK (Pubitemid 46657376)
7. N Robert L Krekow C Stokoe, et al. 2011 Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study Breast Cancer Res Treat 125 115 120 20945091 10.1007/s10549-010-1187-2 1:CAS:528:DC%2BC3cXhsFWgtLjL
8. LD Volk MJ Flister CM Bivens, et al. 2008 Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy Neoplasia 10 613 623 18516298 1:CAS:528:DC%2BD1cXoslWgtbk%3D (Pubitemid 351770305)
9. K Miller M Wang J Gralow, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 18160686 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D
10. E Bria C Nistico F Cuppone, et al. 2006 Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients Cancer 106 2337 2344 16649217 10.1002/cncr.21886 1:CAS:528:DC%2BD28Xls1Srur0%3D (Pubitemid 43787656)
11. M De Laurentiis G Cancello D D'Agostino, et al. 2008 Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol 26 44 53 18165639 10.1200/JCO.2007.11.3787
12. Ferguson T, Wilcken N, Vagg R et al (2007) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev:CD004421
13. IC Henderson DA Berry GD Demetri, et al. 2003 Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 983 12637460 10.1200/JCO.2003.02.063 1:CAS:528:DC%2BD2cXpsVGqs7c%3D (Pubitemid 46594124)
14. Z Kahan G Uhercsak R Hajnal-Papp, et al. 2005 Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer Oncology 68 446 453 16020975 10.1159/000086987 1:CAS:528:DC%2BD2MXnvFyms7Y%3D (Pubitemid 41160976)
15. JC Sachdev M Jahanzeb 2008 Evolution of bevacizumab-based therapy in the management of breast cancer Clin Breast Cancer 8 402 410 18952553 10.3816/CBC.2008.n.048 1:CAS:528:DC%2BD1cXhsVaiurfK
16. M Arnedos S Sutherland S Ashley, et al. 2008 Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer Breast Cancer Res Treat 112 1 4 18060493 10.1007/s10549-007-9826-y 1:CAS:528:DC%2BD1cXhtFOjtrfK
17. S Sugarman C Wasserheit E Hodgman, et al. 2009 A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma Breast Cancer Res Treat 115 609 612 18751888 10.1007/s10549-008-0152-9 1:CAS:528:DC%2BD1MXmsVCrtLk%3D